Welcome to the e-CCO Library!

P471: Efficacy and safety of switching from reference infliximab to biosimilar infliximab in patients with inflammatory bowel disease: first French experience
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Soret P.-A.*1,2, Prieux-Klotz C.1, Avouac J.3, Molto A.3, Dior M.1, Brieau B.1, Dreanic J.1, Camus M.1, Barret M.1, Coriat R.1, Conort O.4, Chast F.4, Goulvestre C.5, Le Jeunne C.6, Dougados M.3, Nahon S.2, Chaussade S.1, Abitbol V.1

Created: Wednesday, 20 February 2019, 10:36 AM
P471: Predictors of bowel damage in long term progression of Crohn’s disease
Year: 2021
Source: ECCO'21 Virtual
Authors: Fernandez Clotet, A.(1);Panes, J.(1);Ricart, E.(1);Castro Poceiro, J.(1);Masamunt, M.C.(1);Rodríguez, S.(2);Caballol, B.(1);Ordas, I.(1);Rimola, J.(2);
Created: Wednesday, 2 June 2021, 4:12 PM
P471: Real-world experience of using Tofacitinib in Ulcerative Colitis in biologic naïve and biologic exposed patients
Year: 2022
Source: ECCO'22
Authors: Cheesbrough, J.(1);Quraishi, M.N.(1);Sharma, N.(1);Nassar, I.(1);
Created: Friday, 11 February 2022, 3:52 PM
P471: Safety analysis of multimatrix mesalazine amongst patients with ulcerative colitis or recurrent diverticulitis ≥ 55 years of age
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

G. Lichtenstein1, K. Barrett2, D. Stefani-Hunyady3, F. Cataldi*4, J. Raskin5

Created: Friday, 22 February 2019, 9:49 AM
P472 Optimising the development of apps for the management of inflammatory bowel disease and participation in clinical trials
Year: 2020
Source:

ECCO'20 Vienna

Authors:

F. Hussain1, M. DeLegge2, M. Copeman3, M.B. Gallagher2, T. Stewart2, G. Georgiev4

Created: Thursday, 30 January 2020, 10:12 AM
P472: Changes in colectomy for Ulcerative Colitis during the last two decades: an in-depth retrospective analysis
Year: 2022
Source: ECCO'22
Authors: Le Cosquer, G.(1);Capirchio, L.(2);Rivière, P.(1);de Suray, N.(2);Poullenot, F.(1);De Vroey, B.(2);Berger, A.(1);Denis, M.A.(2);Zerbib, F.(1);Bachmann, R.(3);Remue, C.(3);Celerier, B.(4);Leonard, D.(3);Denost, Q.(4);Kartheuser, A.(3);Laharie, D.(1);Dewit, O.(2);
Created: Friday, 11 February 2022, 3:52 PM
P472: Cyclosporine versus infliximab in patients with Acute Severe Ulcerative Colitis: A single-centre retrospective study
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Karpavičiūtė, V.(1)*;Kiudelis, G.(2);Kupčinskas, J.(2);Kupčinskas, L.(2);
Created: Friday, 14 July 2023, 11:05 AM
P472: Efficacy of intravenous ustekinumab re-induction in patients with Crohn’s disease with a loss of response
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

V. Heron*1,2, N. Panaccione3, K. Candido1, T. Bessissow1, A. Bitton1, C. Seow3, R. Panaccione3, W. Afif1

Created: Friday, 22 February 2019, 9:41 AM
P472: Faecal calprotectin as a biomarker of early mucosal healing in patients with ulcerative colitis naïve to adalimumab treatment
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

C. Muñoz Villafranca*1, A. Perez de Arenaza2, L. Gómez3, R. Higuera4, A. Munagorri5, M. A. Ogueta6, S. Ibañez7, J. Ortiz de Zárate8, O. Merino3, C. Rodriguez9, O. Nante9, P. Arreba10, P. Ramirez de la Piscina11, I. Rodríguez12, A. Bernal13, J. A. Arévalo13, J. L. Cabriada13

Created: Friday, 22 February 2019, 9:49 AM
P472: Impact of anti-TNF-alfa therapy on colectomy rates and indications for surgery in Ulcerative Colitis: Comparison of two patient cohorts from 2005 to 2007 and 2014 to 2016
Year: 2018
Source: ECCO '18 Vienna
Authors:

S. Kolehmainen1*, A. Lepistö2, M. Färkkilä1,3

Created: Thursday, 21 February 2019, 9:14 AM
P472: Original and biosimilar infliximab: Are they two faces of the same coin? The experience from a pioneer European center
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Cúrdia Gonçalves T.*1, Monteiro S.1, Dias de Castro F.1, Moreira M.J.1, Cotter J.1,2,3

Created: Wednesday, 20 February 2019, 10:36 AM
P472: Payer addressable burden of Crohn’s disease in patients treated with ustekinumab and vedolizumab in the United States
Year: 2021
Source: ECCO'21 Virtual
Authors: Ghosh, T.(1);Smith, I.(2);Fehr, J.(2);Davidson, J.(2);Fan, T.(3);Candela, N.(4);Tsang, C.(5);Koch, T.(5);
Created: Wednesday, 2 June 2021, 4:12 PM
P473 Long-term follow-up of switching from original adalimumab to adalimumab biosimilar: real-world data in IBD
Year: 2020
Source:

ECCO'20 Vienna

Authors:

C. Padilla Suarez, K. Webb, N. Persad, J. Sercombe, E. Tyler, K. Klimova

Created: Thursday, 30 January 2020, 10:12 AM
P473: Clinical and biochemical factors that influence response in inflammatory disease patients receiving tacrolimus
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

I. Rodríguez - Lago*1, 2, O. Merino2, 3, O. Nantes2, 4, C. Muñoz2, 5, U. Aguirre6, J. L. Cabriada1, 2

Created: Friday, 22 February 2019, 9:49 AM
P473: Contrasting the use of 5-ASA in patients with Ulcerative Colitis and Crohn's Disease: A cross-sectional analysis at a tertiary care IBD clinic
Year: 2018
Source: ECCO '18 Vienna
Authors:

M. Alkhattabi*, V. Jairath, N. Chande, P. Walton-Mennill, J. Gregor

Created: Thursday, 21 February 2019, 9:14 AM
P473: Corticosteroid-free clinical remission rates with guselkumab maintenance therapy in patients with moderately to severely active Crohn's disease: Week 48 analyses from the phase 2 GALAXI 1 study
Year: 2023
Source: ECCO’23 Copenhagen
Authors: D'Haens, G.(1)*;Afzali, A.(2);Filip, R.(3);Rolim, A.(4);Terry, N.A.(5);Salese, L.(5);Sahoo, A.(5);Frustaci, M.E.(6);Yang, Z.(6);Andrews, J.M.(7);Danese, S.(8);Hisamatsu, T.(9);
Created: Friday, 14 July 2023, 11:05 AM
P473: Cumulative histological inflammation predicts colorectal neoplasia in ulcerative colitis
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

O. V. Yvellez1, V. Rai*1, J. Hart2, J. R. Turner2, K. El Jurdi1, D. T. Rubin1

Created: Friday, 22 February 2019, 9:41 AM
P473: How to monitor the withdrawal of maintenance treatment with azathioprine in IBD patients with deep remission: results from a prospective study on multiple non invasive tests
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Cassinotti A.*1, Massari A.1, Carmagnola S.1, Molteni P.1, Fociani P.2, Ardizzone S.1

Created: Wednesday, 20 February 2019, 10:36 AM
P473: Real world experience with the Crohn's Disease Exclusion Diet (CDED) in a tertiary IBD clinic
Year: 2022
Source: ECCO'22
Authors: Fliss Isakov, N.(1);Anbar, R.(2);Cooperstein, A.(2);Helbert, G.(2);Hirsch, A.(1);Ron, Y.(1);Thurm, T.(1);Maharshak, N.(1);
Created: Friday, 11 February 2022, 3:52 PM
P473: Ustekinumab and vedolizumab influence on cardiovascular risk factors in patients with Inflammatory Bowel Disease
Year: 2021
Source: ECCO'21 Virtual
Authors: Amiama Roig, C.(1);Suárez Ferrer, C.(1);Poza Cordón, J.(1);Rueda García, J.L.(1);Sánchez Azofra, M.(1);Martín Arranz, E.(1);González Díaz, I.(1);Amor Costa, C.(1);García Ramírez, L.(2);Martín Arranz, M.D.(1);
Created: Wednesday, 2 June 2021, 4:12 PM